Duo Oncology is developing combination cancer medicines designed to deliver multiple active drugs into tumors while limiting exposure to healthy tissues. Its nanomedicine platform is exclusively licensed from the University of Pittsburgh. [1]
Lead candidate DUO-207 combines gemcitabine and paclitaxel in an ultrasmall, tumor-activated formulation. The platform uses a branched polymer with shielding groups and responsive linkers to release its payload under conditions found within tumors. The company’s development targets include pancreatic cancer and later-line lung and breast cancers. [2] [3] [4]
Duo completed GLP toxicology studies for DUO-207 in 2025 as part of preparations for first-in-human testing. Its broader pipeline includes the preclinical DUO-307 and DUO-209 programs. [5] [4]